252 Rationale and study design of the KOV-HIPEC-02 trial: a randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer

Ji Hyun Kim,Eun-Young Park,Dae Hoon Jeong,Yoo-Young Lee,Chel Hoon Choi,Hyun Hoon Chung,Taek Sang Lee,Hye Won Jeon,Shin-Wha Lee,Jeong-Yeol Park,Sung Jong Lee,Seob Jeon,Ki Hyung Kim,Jong Chul Baek,Suk-Joon Chang,Sang-Yoon Park,Myong Cheol Lim

doi:10.1136/ijgc-2024-esgo.1102

252 Rationale and study design of the KOV-HIPEC-02 trial: a randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer

Ji Hyun Kim, Eun-Young Park + Show 15 more

https://doi.org/10.1136/ijgc-2024-esgo.1102

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Publication Date: Mar 1, 2024

Affiliation: Inje University, Samsung Medical Center, Seoul Metropolitan Government, Soonchunhyang University, Pusan National University, Gyeongsang National University, Ajou University

#Platinum-resistant Recurrent Ovarian Cancer #Platinum-resistant Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction/BackgroundHyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery has emerged to achieve a higher concentration of chemotherapeutic agents and treat micro-metastases on peritoneal surfaces. At advanced staged ovarian cancer treated with...

Full Text